New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 29, 2013
10:55 EDTESRX, CTRXSouth Carolina PEBA said last week Catamaran to replace Express Scripts
The South Carolina Public Employee Benefit Authority announced on October 19 that beginning Jan. 1, 2014, Catamaran (CTRX) will replace Express Scripts (ESRX) as the pharmacy benefit manager for the State Health Plan. Reference Link
News For ESRX;CTRX From The Last 14 Days
Check below for free stories on ESRX;CTRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
10:00 EDTCTRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:20 EDTCTRXCatamaran upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
April 14, 2014
15:02 EDTCTRXCatamaran Mat volatility increases, shares near two-year low
Subscribe for More Information
11:09 EDTCTRXOptions with increasing implied volatility: HZNP VJET YOKU CTRX CBS
08:02 EDTCTRXCatamaran recent sell-off overdone, says Jefferies
Jefferies views the recent sell-off in shares of Catamaran as overdone. The firm attributes the move to concerns about the company's ability to meet Q1 consensus and win new contracts. Jefferies expects Catamaran shares to bounce back to the mid-$40s soon after the Q1 report and it keeps a Buy rating on the stock.
April 10, 2014
14:27 EDTCTRXCatamaran sell-off overdone, says UBS
Subscribe for More Information
09:23 EDTCTRXCatamaran channel checks cautious, says Cleveland Research
Cleveland Research said Catamaran checks indicate client frustration with customer service and implementation issues. The firm sees downside to 2014 estimates from higher expenses, system upgrades and potential to pay performance guarantees.
April 9, 2014
11:43 EDTESRXGilead defended by analysts after recent pullback
Subscribe for More Information
08:41 EDTESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
April 7, 2014
07:44 EDTCTRXMarketo to hold a summit
Subscribe for More Information
April 4, 2014
10:53 EDTCTRX High option volume stocks: ITW CTRX WMC LQD IMGN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use